Recent studies have demonstrated that STAT3 is constitutively activated in human NSCLC samples and in a variety of NSCLC lines, independent of activating KRAS or tyrosine kinase mutations [21]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.